David Baxley Spetzler bought $9,540 of CAI
President at Caris Life Sciences, Inc.. 400 shares at an average of $23.85, traded Nov 7, 2025, filed Nov 10, 2025.
Score components
- +20RolePresident
- 0Trade size$10k at market
- -5Relative to holdingsUnder 1% of holdings (0.1%)
- +18Price context4% above the 52-week low; 35% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +9.3%, 3m -10.0%, 6m -35.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0002071953-25-000008, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 7, 2025 | POpen-market purchase Common Stock | +400 | $23.85 | $9,540 | 460,777 | Nov 10, 2025 |
Related signals
Other insiders at Caris Life Sciences, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $239k 7,500 shares | -4% | |
| 60Notable | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $12M 400,000 shares | -63% | |
| 48Moderate | Caris Life Sciences, Inc. | David Baxley Spetzler President | $15M 597,212 shares | -39% | |
| 69Notable | Caris Life Sciences, Inc. | Jon Halbert director | $990k 68,000 shares | +11% | |
| 69Notable | Caris Life Sciences, Inc. | Jeff L Vacirca director | $501k 31,050 shares | +167% | |
| 15Weak | Caris Life Sciences, Inc. | Luke Thomas Power See Remarks | $1.7M 62,250 shares | -38% | |
| 61Notable | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $101k 4,184 shares | +84% | |
| 59Moderate | Caris Life Sciences, Inc. | Brian J Brille See Remarks | $630k 30,000 shares | +23% | |
| 47Moderate | Caris Life Sciences, Inc. | John Russel Denton See Remarks | $158k 7,500 shares | +6% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.